CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 66% of retail investor accounts lose money when trading CFDs with this provider (Saxo Bank). You should consider whether you understand how CFDs, FX or any of our other products work and whether you can afford to take the high risk of losing your money.

Equity Research; Wuhan Coronavirus v SARS

Wuhan Coronavirus facts

Despite having visited China numerous times, and being married to a Taiwanese, I had not actually heard of Wuhan before 2020. But I am now versed, thanks to the Wuhan Coronavirus.

Wuhan, the state capital of Hubei province in central China, has a population of c. 11m (> Greater London c.8.1m). It has the distinction of having been China’s capital city on two occasions, in 1927 and for ten months in 1937. Due to its prominence as a transport hub it is nicknamed “China’s thoroughfare”.

The Chinese government has put Wuhan in quarantine lockdown intending to slow the spread of the virus to neighbouring cities. This is a good first step against virus transmission, assuming the quarantine is kept in place. The government has also banned Chinese tour groups from going overseas and pinpointed the source of the outbreak, the Huanan Seafood Market in Wuhan.

A major supporting factor is China’s geography. Wuhan is c.838 km from Shanghai, 1,152km from Beijing and 919km from HK. It is c. 200 km to other large provincial cities. This factor reduces the risk of airborne viral transmission.

Whilst viruses mutate and develop resistances, the Wuhan coronavirus can jump from animals to humans (“zoonosis”) increasing its reach. Both Ebola and SARS (“severe acute respiratory syndrome”) had this capability. This increases the potential infection rate, but not necessarily the fatality rate.

Also negative is data manipulation, China’s leadership is likely to underquote the virus stats on reported cases and deaths. Due to the extended Lunar Chinese New Year Holiday these factors could create data gaps that change perceptions of the virus spread.

Source: National Health Commission of the PRC (29th January 2019)

Economic impact of Wuhan coronavirus (WC)

Critical factors in a scenario analysis estimating the virus’s economic impact i.e. the outcome include whether global transmission occurs, i.e. the virus spread, its duration, the effectiveness of countermeasures and the medical response as first order effects.

At this stage, both the “attack rate” (“R0”) and the incubation period can only be estimated. The attack rate or transmissibility of a virus, its reproductive number, Ro is estimated at 2.6 i.e. the number of people that can catch the disease from 1 infected person. The estimate is from a wide range of between 2x and 3.1x. The incubation period estimate is also wide from 2-14 days.

We need to consider possible economic stabilizers that may work to mitigate the GDP drag / uncertainty created by the virus. The Wuhan Coronavirus issue comprises multifactor considerations. The table below gives examples of possible outcomes to different scenarios.

Wuhan Coronavirus Spread Duration Countermeasures Offsetting measures Outcome
Optimistic China <3 months Quarantine/ Travel Restrictions/ Vaccine

Oil ($5)/bbl

PBoC cuts rates

China GDP


Base Case China/ SE Asia 3-6 months Quarantine/ Travel Restrictions PBoC cuts rates Global GDP -½%
Negative Global 6+ months Quarantine None Global GDP -1%

It is early days but the optimistic scenario appears credible given i) the efforts to contain the virus ii) the extensive countermeasures and offsetting factors such as iii) the observed drop in crude oil prices (YTD Brent $59.50 -10.3%) and other industrial commodities (YTD Copper $5702.50 – 8.1%).

The “outcome” possibilities are credible on the basis that SARS cost an estimated 2% of China GDP. The Wuhan Coronavirus is likely to have an impact on Chinese GDP even in an optimistic scenario, of c. -1%/ -2%, in the context of a 6% growth rate.

SARS – a brief recap and index comparison

The SARS outbreak in 2003 originated in Hong Kong and its transmission was primarily airborne. There were 8,273 cases of the SARS virus and 775 deaths, a fatality rate of 9.6% primarily amongst the elderly. The current fatality rate for Wuhan Coronavirus is c. 2.2%.

The extract below compares SARS duration and fatality curves with the Ebola virus outbreak in the DRC (a vaccine for Ebola is available). Ebola had a much higher fatality rate (66.6%) but had lower spread. This is likely due to the lower linkage between high population densities outside the DRC.


By August 2003 SARS had spread to 29 countries within a 10 week period. After c. 1 month the Wuhan Coronavirus cases have been reported in 20 other countries but without any fatalities so far outside China.

The impact of the SARS virus originated in Hong Kong where the economy experienced a demand shock. The impact of SARS on China GDP was estimated at -2%. However in 2003 Hong Kong GDP (c. $161.4bn) was c.9.7% of China GDP ($1.66trn) v. c. 2.6% in 2019 suggesting a similar outbreak now would be more muted in terms of China GDP.

Concerns over the SARS virus impact on GDP growth led to a brief drop in Hong Kong’s Hang Seng Index (the most relevant proxy at the time) over Q1 2003. However over January to August 2003 the Hang Seng Index climbed 16.87% reversing the SARS Q1 losses and ended 2003 showing excellent returns (+34.28%).

Hang Seng Year Open Year High Year Low Year Close Annual Change (%)
2003 9,365.5 12,594.42 8,409.01 12,575.94 +34.28

Over the relevant period in 2003 (January to August) the Hang Seng added 16.87%. This included a tough period over January to April 2003

Hang Seng Jan-Aug 2003 Open Jan-Aug 2003 High Jan-Aug 2003 Low Jan-Aug 2003 Close Change (%)
2003 9,333.64 10,934.52 8,331.87 10,908.99 +16.87


Hang Seng Year Open Jan 2019 High Jan 2019 Low Jan 30th 2019 3rd-30th Jan 2019 Change (%)
2019 28,249.37 29,056.42 26,330.05 26,449.13 -6.37%

The SARS impact on the US S&P 500 (c. -8%) was a Q1 factor that had reversed over Q2 and had little bearing on US equity performance over 2003. As is normal where a market moving event originates outside the USA, the impact on New York stocks is muted and short-term.

US S&P 500 Jan-Dec 2003


The comparison between Wuhan Coronavirus and SARS, insofar as the two events suggests:-

  1. The Wuhan Coronavirus impact is likely a Q1 event whose effect should reverse over the course of 2020.
  2. The epicentre of the GDP impact is likely to be China/ Hong Kong with an expected drag on GDP growth (c.6%) of -2%.
  3. The Hang Seng’s YTD drop of 6.37% is in typical ‘correction’ territory and is a buying opportunity if/ when the virus data abates. The drop is a good steer on the likely Shanghai re-opening expected to re-open c. 8% down.
  4. The impact on US, EU and other global equity markets is likely to be short-term and relatively muted assuming a similar SARS virus spread, duration and effective countermeasures.

Subscribe to our Award-winning Newsletter

We provide daily market data in the form of our award-winning newsletter, The Morning Call and The Market Close.
You can subscribe to this information at any time to help you make the most of your investment.

Quick Sign-up

Important Information

Key to Material Interests:

Please be aware that the following disclosures of Material Interests are relevant to this research note:


  1. The analyst has a personal holding in the securities issued by the company or of derivatives linked to the price of the company’s securities.
  2. Collins Sarri Statham Investments Ltd has clients who hold either shares or CFD positions in this security.

Analyst Certification:

The report’s author certifies that this research report accurately states his personal views about the subject securities, which is reflected in the ratings as well as the substance of the reports.


Collins Sarri Statham Investments Ltd (CSS) does not in any of its publications take into account any particular recipient's investment objectives, financial situation, and specific needs and demands. Therefore, all CSS publications are, unless otherwise specifically stated, intended for informational and/or marketing purposes only.CSS shall not be responsible for any loss arising from any investment based on a perceived recommendation.

No publication (including recommendations) shall be construed as a representation or warranty that the recipient will profit, nor avoid sustaining losses, from trading in accordance with a trading strategy set forth in a publication.

This research is non-independent and is classified as a Marketing Communication under FCA rules detailed in their Conduct of Business Rulebook (COBS). As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition of dealing ahead of the dissemination of investment research outlined in COBS 12.2.18.

Risk Warning:

Trading in the products and services offered by Collins Sarri Statham Investments Ltd (CSS) may, result in losses as well as profits as the value of investments may go down as well as up. You may not get back the full amount you have invested. Any reference to past performance should not be viewed as an indication of any future performance. Investments held in overseas markets are subject to the effects of changes in exchange rates which will impact on the value of the underlying investment. Investments made in AIM and penny shares carry an increased risk due to the difficulty in creating a market in these shares. There may be a substantial difference in the buy and sell price. Leveraged products such as Contracts for Difference (CFDs), derivatives, commodities & Foreign Exchange (FX), carry a higher risk to your capital and they can lose their value rapidly.

Speculative Trading is not Suitable for all Investors

The information contained herein is based on materials and sources that we believe to be reliable however we make no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Please note that the figures shown may, in some instances, be rounded to the nearest penny. Prices can move sharply from those quoted in this document. Current prices can be verified by calling one of our brokers. CSS is under no obligation to update the information contained herein. Neither CSS, nor its affiliates, nor its employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from the use of this document.

Get Started with CSS

Open an Account

Subscribe to our award winning daily newsletter

Voted "Best Market Newsletter" in 2012, 2014, 2015 and 2017 by the City of London Wealth Management Awards

Subscribe to our newsletter (Popup)

By signing up to our free email, you are consenting to receive these promotions. The newsletter is sent up to three times per day during the week and up to once per day over the weekend and is directed at UK residents. The newsletter contains company news, market movements, CSS research and promotions and breaking economic news. Occasionally our newsletter will contain advertisements from trusted partners. However, we will never give, sell or rent your email address to any other companies. If you want to stop receiving our free emails you can unsubscribe at any time by clicking on the link at the bottom of each email. You can read our privacy policy here.

No, thank you I am already subscribed